Global New Molecular Entities (NME) Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global New Molecular Entities (NME) Drugs market size was valued at US$ 242242 million in 2025 and is forecast to a readjusted size of US$ 383098 million by 2032 with a CAGR of 6.7% during review period.
In 2025, global New Molecular Entities (NME) Drugs reached approximately 96.94 M Units, with an average global market price of around 2428 USD per Unit.
New Molecular Entity (NME) drugs are pharmaceutical products that contain an active ingredient never before approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities for use in humans. An NME is characterized by a novel chemical structure or molecular composition, meaning the active substance has not previously been marketed or authorized in any drug product. NMEs represent true pharmaceutical innovation, as they introduce new mechanisms of action, new biological targets, or new therapeutic approaches for the prevention, diagnosis, or treatment of disease. They are typically approved by the FDA under a New Drug Application (NDA) (for small-molecule drugs) and are closely tracked by regulators and the pharmaceutical industry as a key indicator of research and development (R&D) productivity and innovation strength.
The upstream raw materials for new molecular entity (NME) drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients, etc. Typical suppliers include Pfizer, Roche, Merck, AstraZeneca, etc. The downstream applications are mainly in the treatment of oncology, immune diseases, cardiovascular diseases, etc.
The single-line production capacity of new molecular entity (NME) drugs varies greatly depending on the type of drug molecule, process complexity, equipment scale and production mode, and the industry gross profit margin is usually in the range of 60%-80%.
This report is a detailed and comprehensive analysis for global New Molecular Entities (NME) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global New Molecular Entities (NME) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for New Molecular Entities (NME) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global New Molecular Entities (NME) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Merck, Pfizer, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Bayer, GSK, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
New Molecular Entities (NME) Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe New Molecular Entities (NME) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of New Molecular Entities (NME) Drugs, with price, sales quantity, revenue, and global market share of New Molecular Entities (NME) Drugs from 2021 to 2026.
Chapter 3, the New Molecular Entities (NME) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the New Molecular Entities (NME) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and New Molecular Entities (NME) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of New Molecular Entities (NME) Drugs.
Chapter 14 and 15, to describe New Molecular Entities (NME) Drugs sales channel, distributors, customers, research findings and conclusion.
In 2025, global New Molecular Entities (NME) Drugs reached approximately 96.94 M Units, with an average global market price of around 2428 USD per Unit.
New Molecular Entity (NME) drugs are pharmaceutical products that contain an active ingredient never before approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities for use in humans. An NME is characterized by a novel chemical structure or molecular composition, meaning the active substance has not previously been marketed or authorized in any drug product. NMEs represent true pharmaceutical innovation, as they introduce new mechanisms of action, new biological targets, or new therapeutic approaches for the prevention, diagnosis, or treatment of disease. They are typically approved by the FDA under a New Drug Application (NDA) (for small-molecule drugs) and are closely tracked by regulators and the pharmaceutical industry as a key indicator of research and development (R&D) productivity and innovation strength.
The upstream raw materials for new molecular entity (NME) drugs mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients, etc. Typical suppliers include Pfizer, Roche, Merck, AstraZeneca, etc. The downstream applications are mainly in the treatment of oncology, immune diseases, cardiovascular diseases, etc.
The single-line production capacity of new molecular entity (NME) drugs varies greatly depending on the type of drug molecule, process complexity, equipment scale and production mode, and the industry gross profit margin is usually in the range of 60%-80%.
This report is a detailed and comprehensive analysis for global New Molecular Entities (NME) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global New Molecular Entities (NME) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global New Molecular Entities (NME) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for New Molecular Entities (NME) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global New Molecular Entities (NME) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Merck, Pfizer, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Bayer, GSK, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
New Molecular Entities (NME) Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Small Molecules
- Monoclonal Antibodies
- ADCs
- Others
- Oral Drugs
- Injectable Drugs
- Others
- Receptor Agonists
- Enzyme Inhibitors
- Others
- Cancer Diseases
- Immune Diseases
- Cardiovascular Diseases
- Others
- Roche
- Novartis
- Merck
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Bristol Myers Squibb
- Bayer
- GSK
- Daiichi Sankyo
- Amgen
- Eli Lilly and Company
- AbbVie
- Sanofi
- Takeda
- Boehringer Ingelheim
- Beigene, Ltd.
- Jiangsu Hengrui Medicine
- INNOVENT BIOLOGICS(SUZHOU)
- Betta Pharmaceuticals
- Remegen Co.,Ltd.
- Shanghai Allist Pharmaceuticals
- Innocare
- Huiyu Pharmaceuticals
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe New Molecular Entities (NME) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of New Molecular Entities (NME) Drugs, with price, sales quantity, revenue, and global market share of New Molecular Entities (NME) Drugs from 2021 to 2026.
Chapter 3, the New Molecular Entities (NME) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the New Molecular Entities (NME) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and New Molecular Entities (NME) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of New Molecular Entities (NME) Drugs.
Chapter 14 and 15, to describe New Molecular Entities (NME) Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Small Molecules
1.3.3 Monoclonal Antibodies
1.3.4 ADCs
1.3.5 Others
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Oral Drugs
1.4.3 Injectable Drugs
1.4.4 Others
1.5 Market Analysis by Action Mechanism
1.5.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Action Mechanism: 2021 Versus 2025 Versus 2032
1.5.2 Receptor Agonists
1.5.3 Enzyme Inhibitors
1.5.4 Others
1.6 Market Analysis by Application
1.6.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Cancer Diseases
1.6.3 Immune Diseases
1.6.4 Cardiovascular Diseases
1.6.5 Others
1.7 Global New Molecular Entities (NME) Drugs Market Size & Forecast
1.7.1 Global New Molecular Entities (NME) Drugs Consumption Value (2021 & 2025 & 2032)
1.7.2 Global New Molecular Entities (NME) Drugs Sales Quantity (2021-2032)
1.7.3 Global New Molecular Entities (NME) Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche New Molecular Entities (NME) Drugs Product and Services
2.1.4 Roche New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis New Molecular Entities (NME) Drugs Product and Services
2.2.4 Novartis New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck New Molecular Entities (NME) Drugs Product and Services
2.3.4 Merck New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Merck Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer New Molecular Entities (NME) Drugs Product and Services
2.4.4 Pfizer New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Pfizer Recent Developments/Updates
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca New Molecular Entities (NME) Drugs Product and Services
2.5.4 AstraZeneca New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 AstraZeneca Recent Developments/Updates
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson New Molecular Entities (NME) Drugs Product and Services
2.6.4 Johnson & Johnson New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Johnson & Johnson Recent Developments/Updates
2.7 Bristol Myers Squibb
2.7.1 Bristol Myers Squibb Details
2.7.2 Bristol Myers Squibb Major Business
2.7.3 Bristol Myers Squibb New Molecular Entities (NME) Drugs Product and Services
2.7.4 Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Bristol Myers Squibb Recent Developments/Updates
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer New Molecular Entities (NME) Drugs Product and Services
2.8.4 Bayer New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Bayer Recent Developments/Updates
2.9 GSK
2.9.1 GSK Details
2.9.2 GSK Major Business
2.9.3 GSK New Molecular Entities (NME) Drugs Product and Services
2.9.4 GSK New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 GSK Recent Developments/Updates
2.10 Daiichi Sankyo
2.10.1 Daiichi Sankyo Details
2.10.2 Daiichi Sankyo Major Business
2.10.3 Daiichi Sankyo New Molecular Entities (NME) Drugs Product and Services
2.10.4 Daiichi Sankyo New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Daiichi Sankyo Recent Developments/Updates
2.11 Amgen
2.11.1 Amgen Details
2.11.2 Amgen Major Business
2.11.3 Amgen New Molecular Entities (NME) Drugs Product and Services
2.11.4 Amgen New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Amgen Recent Developments/Updates
2.12 Eli Lilly and Company
2.12.1 Eli Lilly and Company Details
2.12.2 Eli Lilly and Company Major Business
2.12.3 Eli Lilly and Company New Molecular Entities (NME) Drugs Product and Services
2.12.4 Eli Lilly and Company New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Eli Lilly and Company Recent Developments/Updates
2.13 AbbVie
2.13.1 AbbVie Details
2.13.2 AbbVie Major Business
2.13.3 AbbVie New Molecular Entities (NME) Drugs Product and Services
2.13.4 AbbVie New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 AbbVie Recent Developments/Updates
2.14 Sanofi
2.14.1 Sanofi Details
2.14.2 Sanofi Major Business
2.14.3 Sanofi New Molecular Entities (NME) Drugs Product and Services
2.14.4 Sanofi New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Sanofi Recent Developments/Updates
2.15 Takeda
2.15.1 Takeda Details
2.15.2 Takeda Major Business
2.15.3 Takeda New Molecular Entities (NME) Drugs Product and Services
2.15.4 Takeda New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Takeda Recent Developments/Updates
2.16 Boehringer Ingelheim
2.16.1 Boehringer Ingelheim Details
2.16.2 Boehringer Ingelheim Major Business
2.16.3 Boehringer Ingelheim New Molecular Entities (NME) Drugs Product and Services
2.16.4 Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Boehringer Ingelheim Recent Developments/Updates
2.17 Beigene, Ltd.
2.17.1 Beigene, Ltd. Details
2.17.2 Beigene, Ltd. Major Business
2.17.3 Beigene, Ltd. New Molecular Entities (NME) Drugs Product and Services
2.17.4 Beigene, Ltd. New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Beigene, Ltd. Recent Developments/Updates
2.18 Jiangsu Hengrui Medicine
2.18.1 Jiangsu Hengrui Medicine Details
2.18.2 Jiangsu Hengrui Medicine Major Business
2.18.3 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product and Services
2.18.4 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Jiangsu Hengrui Medicine Recent Developments/Updates
2.19 INNOVENT BIOLOGICS(SUZHOU)
2.19.1 INNOVENT BIOLOGICS(SUZHOU) Details
2.19.2 INNOVENT BIOLOGICS(SUZHOU) Major Business
2.19.3 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product and Services
2.19.4 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 INNOVENT BIOLOGICS(SUZHOU) Recent Developments/Updates
2.20 Betta Pharmaceuticals
2.20.1 Betta Pharmaceuticals Details
2.20.2 Betta Pharmaceuticals Major Business
2.20.3 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.20.4 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Betta Pharmaceuticals Recent Developments/Updates
2.21 Remegen Co.,Ltd.
2.21.1 Remegen Co.,Ltd. Details
2.21.2 Remegen Co.,Ltd. Major Business
2.21.3 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product and Services
2.21.4 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Remegen Co.,Ltd. Recent Developments/Updates
2.22 Shanghai Allist Pharmaceuticals
2.22.1 Shanghai Allist Pharmaceuticals Details
2.22.2 Shanghai Allist Pharmaceuticals Major Business
2.22.3 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.22.4 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 Shanghai Allist Pharmaceuticals Recent Developments/Updates
2.23 Innocare
2.23.1 Innocare Details
2.23.2 Innocare Major Business
2.23.3 Innocare New Molecular Entities (NME) Drugs Product and Services
2.23.4 Innocare New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Innocare Recent Developments/Updates
2.24 Huiyu Pharmaceuticals
2.24.1 Huiyu Pharmaceuticals Details
2.24.2 Huiyu Pharmaceuticals Major Business
2.24.3 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.24.4 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Huiyu Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEW MOLECULAR ENTITIES (NME) DRUGS BY MANUFACTURER
3.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global New Molecular Entities (NME) Drugs Revenue by Manufacturer (2021-2026)
3.3 Global New Molecular Entities (NME) Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of New Molecular Entities (NME) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 New Molecular Entities (NME) Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 New Molecular Entities (NME) Drugs Manufacturer Market Share in 2025
3.5 New Molecular Entities (NME) Drugs Market: Overall Company Footprint Analysis
3.5.1 New Molecular Entities (NME) Drugs Market: Region Footprint
3.5.2 New Molecular Entities (NME) Drugs Market: Company Product Type Footprint
3.5.3 New Molecular Entities (NME) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global New Molecular Entities (NME) Drugs Market Size by Region
4.1.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2032)
4.1.3 Global New Molecular Entities (NME) Drugs Average Price by Region (2021-2032)
4.2 North America New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.3 Europe New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.5 South America New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
5.2 Global New Molecular Entities (NME) Drugs Consumption Value by Type (2021-2032)
5.3 Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
6.2 Global New Molecular Entities (NME) Drugs Consumption Value by Application (2021-2032)
6.3 Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
7.2 North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
7.3 North America New Molecular Entities (NME) Drugs Market Size by Country
7.3.1 North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
8.2 Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
8.3 Europe New Molecular Entities (NME) Drugs Market Size by Country
8.3.1 Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific New Molecular Entities (NME) Drugs Market Size by Region
9.3.1 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
10.2 South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
10.3 South America New Molecular Entities (NME) Drugs Market Size by Country
10.3.1 South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa New Molecular Entities (NME) Drugs Market Size by Country
11.3.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 New Molecular Entities (NME) Drugs Market Drivers
12.2 New Molecular Entities (NME) Drugs Market Restraints
12.3 New Molecular Entities (NME) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of New Molecular Entities (NME) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of New Molecular Entities (NME) Drugs
13.3 New Molecular Entities (NME) Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 New Molecular Entities (NME) Drugs Typical Distributors
14.3 New Molecular Entities (NME) Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Small Molecules
1.3.3 Monoclonal Antibodies
1.3.4 ADCs
1.3.5 Others
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Oral Drugs
1.4.3 Injectable Drugs
1.4.4 Others
1.5 Market Analysis by Action Mechanism
1.5.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Action Mechanism: 2021 Versus 2025 Versus 2032
1.5.2 Receptor Agonists
1.5.3 Enzyme Inhibitors
1.5.4 Others
1.6 Market Analysis by Application
1.6.1 Overview: Global New Molecular Entities (NME) Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Cancer Diseases
1.6.3 Immune Diseases
1.6.4 Cardiovascular Diseases
1.6.5 Others
1.7 Global New Molecular Entities (NME) Drugs Market Size & Forecast
1.7.1 Global New Molecular Entities (NME) Drugs Consumption Value (2021 & 2025 & 2032)
1.7.2 Global New Molecular Entities (NME) Drugs Sales Quantity (2021-2032)
1.7.3 Global New Molecular Entities (NME) Drugs Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche New Molecular Entities (NME) Drugs Product and Services
2.1.4 Roche New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Roche Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis New Molecular Entities (NME) Drugs Product and Services
2.2.4 Novartis New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Novartis Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck New Molecular Entities (NME) Drugs Product and Services
2.3.4 Merck New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Merck Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer New Molecular Entities (NME) Drugs Product and Services
2.4.4 Pfizer New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Pfizer Recent Developments/Updates
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca New Molecular Entities (NME) Drugs Product and Services
2.5.4 AstraZeneca New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 AstraZeneca Recent Developments/Updates
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson New Molecular Entities (NME) Drugs Product and Services
2.6.4 Johnson & Johnson New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Johnson & Johnson Recent Developments/Updates
2.7 Bristol Myers Squibb
2.7.1 Bristol Myers Squibb Details
2.7.2 Bristol Myers Squibb Major Business
2.7.3 Bristol Myers Squibb New Molecular Entities (NME) Drugs Product and Services
2.7.4 Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Bristol Myers Squibb Recent Developments/Updates
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer New Molecular Entities (NME) Drugs Product and Services
2.8.4 Bayer New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Bayer Recent Developments/Updates
2.9 GSK
2.9.1 GSK Details
2.9.2 GSK Major Business
2.9.3 GSK New Molecular Entities (NME) Drugs Product and Services
2.9.4 GSK New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 GSK Recent Developments/Updates
2.10 Daiichi Sankyo
2.10.1 Daiichi Sankyo Details
2.10.2 Daiichi Sankyo Major Business
2.10.3 Daiichi Sankyo New Molecular Entities (NME) Drugs Product and Services
2.10.4 Daiichi Sankyo New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Daiichi Sankyo Recent Developments/Updates
2.11 Amgen
2.11.1 Amgen Details
2.11.2 Amgen Major Business
2.11.3 Amgen New Molecular Entities (NME) Drugs Product and Services
2.11.4 Amgen New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Amgen Recent Developments/Updates
2.12 Eli Lilly and Company
2.12.1 Eli Lilly and Company Details
2.12.2 Eli Lilly and Company Major Business
2.12.3 Eli Lilly and Company New Molecular Entities (NME) Drugs Product and Services
2.12.4 Eli Lilly and Company New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Eli Lilly and Company Recent Developments/Updates
2.13 AbbVie
2.13.1 AbbVie Details
2.13.2 AbbVie Major Business
2.13.3 AbbVie New Molecular Entities (NME) Drugs Product and Services
2.13.4 AbbVie New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 AbbVie Recent Developments/Updates
2.14 Sanofi
2.14.1 Sanofi Details
2.14.2 Sanofi Major Business
2.14.3 Sanofi New Molecular Entities (NME) Drugs Product and Services
2.14.4 Sanofi New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Sanofi Recent Developments/Updates
2.15 Takeda
2.15.1 Takeda Details
2.15.2 Takeda Major Business
2.15.3 Takeda New Molecular Entities (NME) Drugs Product and Services
2.15.4 Takeda New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Takeda Recent Developments/Updates
2.16 Boehringer Ingelheim
2.16.1 Boehringer Ingelheim Details
2.16.2 Boehringer Ingelheim Major Business
2.16.3 Boehringer Ingelheim New Molecular Entities (NME) Drugs Product and Services
2.16.4 Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Boehringer Ingelheim Recent Developments/Updates
2.17 Beigene, Ltd.
2.17.1 Beigene, Ltd. Details
2.17.2 Beigene, Ltd. Major Business
2.17.3 Beigene, Ltd. New Molecular Entities (NME) Drugs Product and Services
2.17.4 Beigene, Ltd. New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Beigene, Ltd. Recent Developments/Updates
2.18 Jiangsu Hengrui Medicine
2.18.1 Jiangsu Hengrui Medicine Details
2.18.2 Jiangsu Hengrui Medicine Major Business
2.18.3 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product and Services
2.18.4 Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Jiangsu Hengrui Medicine Recent Developments/Updates
2.19 INNOVENT BIOLOGICS(SUZHOU)
2.19.1 INNOVENT BIOLOGICS(SUZHOU) Details
2.19.2 INNOVENT BIOLOGICS(SUZHOU) Major Business
2.19.3 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product and Services
2.19.4 INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 INNOVENT BIOLOGICS(SUZHOU) Recent Developments/Updates
2.20 Betta Pharmaceuticals
2.20.1 Betta Pharmaceuticals Details
2.20.2 Betta Pharmaceuticals Major Business
2.20.3 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.20.4 Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Betta Pharmaceuticals Recent Developments/Updates
2.21 Remegen Co.,Ltd.
2.21.1 Remegen Co.,Ltd. Details
2.21.2 Remegen Co.,Ltd. Major Business
2.21.3 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product and Services
2.21.4 Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Remegen Co.,Ltd. Recent Developments/Updates
2.22 Shanghai Allist Pharmaceuticals
2.22.1 Shanghai Allist Pharmaceuticals Details
2.22.2 Shanghai Allist Pharmaceuticals Major Business
2.22.3 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.22.4 Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 Shanghai Allist Pharmaceuticals Recent Developments/Updates
2.23 Innocare
2.23.1 Innocare Details
2.23.2 Innocare Major Business
2.23.3 Innocare New Molecular Entities (NME) Drugs Product and Services
2.23.4 Innocare New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Innocare Recent Developments/Updates
2.24 Huiyu Pharmaceuticals
2.24.1 Huiyu Pharmaceuticals Details
2.24.2 Huiyu Pharmaceuticals Major Business
2.24.3 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
2.24.4 Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Huiyu Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEW MOLECULAR ENTITIES (NME) DRUGS BY MANUFACTURER
3.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global New Molecular Entities (NME) Drugs Revenue by Manufacturer (2021-2026)
3.3 Global New Molecular Entities (NME) Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of New Molecular Entities (NME) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 New Molecular Entities (NME) Drugs Manufacturer Market Share in 2025
3.4.3 Top 6 New Molecular Entities (NME) Drugs Manufacturer Market Share in 2025
3.5 New Molecular Entities (NME) Drugs Market: Overall Company Footprint Analysis
3.5.1 New Molecular Entities (NME) Drugs Market: Region Footprint
3.5.2 New Molecular Entities (NME) Drugs Market: Company Product Type Footprint
3.5.3 New Molecular Entities (NME) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global New Molecular Entities (NME) Drugs Market Size by Region
4.1.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2032)
4.1.2 Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2032)
4.1.3 Global New Molecular Entities (NME) Drugs Average Price by Region (2021-2032)
4.2 North America New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.3 Europe New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.5 South America New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
5.2 Global New Molecular Entities (NME) Drugs Consumption Value by Type (2021-2032)
5.3 Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
6.2 Global New Molecular Entities (NME) Drugs Consumption Value by Application (2021-2032)
6.3 Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
7.2 North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
7.3 North America New Molecular Entities (NME) Drugs Market Size by Country
7.3.1 North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
7.3.2 North America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
8.2 Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
8.3 Europe New Molecular Entities (NME) Drugs Market Size by Country
8.3.1 Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
8.3.2 Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific New Molecular Entities (NME) Drugs Market Size by Region
9.3.1 Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
10.2 South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
10.3 South America New Molecular Entities (NME) Drugs Market Size by Country
10.3.1 South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
10.3.2 South America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa New Molecular Entities (NME) Drugs Market Size by Country
11.3.1 Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 New Molecular Entities (NME) Drugs Market Drivers
12.2 New Molecular Entities (NME) Drugs Market Restraints
12.3 New Molecular Entities (NME) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of New Molecular Entities (NME) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of New Molecular Entities (NME) Drugs
13.3 New Molecular Entities (NME) Drugs Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 New Molecular Entities (NME) Drugs Typical Distributors
14.3 New Molecular Entities (NME) Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global New Molecular Entities (NME) Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global New Molecular Entities (NME) Drugs Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global New Molecular Entities (NME) Drugs Consumption Value by Action Mechanism, (USD Million), 2021 & 2025 & 2032
Table 4. Global New Molecular Entities (NME) Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Roche Basic Information, Manufacturing Base and Competitors
Table 6. Roche Major Business
Table 7. Roche New Molecular Entities (NME) Drugs Product and Services
Table 8. Roche New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Roche Recent Developments/Updates
Table 10. Novartis Basic Information, Manufacturing Base and Competitors
Table 11. Novartis Major Business
Table 12. Novartis New Molecular Entities (NME) Drugs Product and Services
Table 13. Novartis New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Novartis Recent Developments/Updates
Table 15. Merck Basic Information, Manufacturing Base and Competitors
Table 16. Merck Major Business
Table 17. Merck New Molecular Entities (NME) Drugs Product and Services
Table 18. Merck New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Merck Recent Developments/Updates
Table 20. Pfizer Basic Information, Manufacturing Base and Competitors
Table 21. Pfizer Major Business
Table 22. Pfizer New Molecular Entities (NME) Drugs Product and Services
Table 23. Pfizer New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Pfizer Recent Developments/Updates
Table 25. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 26. AstraZeneca Major Business
Table 27. AstraZeneca New Molecular Entities (NME) Drugs Product and Services
Table 28. AstraZeneca New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. AstraZeneca Recent Developments/Updates
Table 30. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 31. Johnson & Johnson Major Business
Table 32. Johnson & Johnson New Molecular Entities (NME) Drugs Product and Services
Table 33. Johnson & Johnson New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Johnson & Johnson Recent Developments/Updates
Table 35. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 36. Bristol Myers Squibb Major Business
Table 37. Bristol Myers Squibb New Molecular Entities (NME) Drugs Product and Services
Table 38. Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Bristol Myers Squibb Recent Developments/Updates
Table 40. Bayer Basic Information, Manufacturing Base and Competitors
Table 41. Bayer Major Business
Table 42. Bayer New Molecular Entities (NME) Drugs Product and Services
Table 43. Bayer New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Bayer Recent Developments/Updates
Table 45. GSK Basic Information, Manufacturing Base and Competitors
Table 46. GSK Major Business
Table 47. GSK New Molecular Entities (NME) Drugs Product and Services
Table 48. GSK New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. GSK Recent Developments/Updates
Table 50. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 51. Daiichi Sankyo Major Business
Table 52. Daiichi Sankyo New Molecular Entities (NME) Drugs Product and Services
Table 53. Daiichi Sankyo New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Daiichi Sankyo Recent Developments/Updates
Table 55. Amgen Basic Information, Manufacturing Base and Competitors
Table 56. Amgen Major Business
Table 57. Amgen New Molecular Entities (NME) Drugs Product and Services
Table 58. Amgen New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Amgen Recent Developments/Updates
Table 60. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 61. Eli Lilly and Company Major Business
Table 62. Eli Lilly and Company New Molecular Entities (NME) Drugs Product and Services
Table 63. Eli Lilly and Company New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Eli Lilly and Company Recent Developments/Updates
Table 65. AbbVie Basic Information, Manufacturing Base and Competitors
Table 66. AbbVie Major Business
Table 67. AbbVie New Molecular Entities (NME) Drugs Product and Services
Table 68. AbbVie New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. AbbVie Recent Developments/Updates
Table 70. Sanofi Basic Information, Manufacturing Base and Competitors
Table 71. Sanofi Major Business
Table 72. Sanofi New Molecular Entities (NME) Drugs Product and Services
Table 73. Sanofi New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Sanofi Recent Developments/Updates
Table 75. Takeda Basic Information, Manufacturing Base and Competitors
Table 76. Takeda Major Business
Table 77. Takeda New Molecular Entities (NME) Drugs Product and Services
Table 78. Takeda New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Takeda Recent Developments/Updates
Table 80. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 81. Boehringer Ingelheim Major Business
Table 82. Boehringer Ingelheim New Molecular Entities (NME) Drugs Product and Services
Table 83. Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Beigene, Ltd. Basic Information, Manufacturing Base and Competitors
Table 86. Beigene, Ltd. Major Business
Table 87. Beigene, Ltd. New Molecular Entities (NME) Drugs Product and Services
Table 88. Beigene, Ltd. New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. Beigene, Ltd. Recent Developments/Updates
Table 90. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 91. Jiangsu Hengrui Medicine Major Business
Table 92. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product and Services
Table 93. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 95. INNOVENT BIOLOGICS(SUZHOU) Basic Information, Manufacturing Base and Competitors
Table 96. INNOVENT BIOLOGICS(SUZHOU) Major Business
Table 97. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product and Services
Table 98. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 99. INNOVENT BIOLOGICS(SUZHOU) Recent Developments/Updates
Table 100. Betta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 101. Betta Pharmaceuticals Major Business
Table 102. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 103. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Betta Pharmaceuticals Recent Developments/Updates
Table 105. Remegen Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 106. Remegen Co.,Ltd. Major Business
Table 107. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product and Services
Table 108. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Remegen Co.,Ltd. Recent Developments/Updates
Table 110. Shanghai Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 111. Shanghai Allist Pharmaceuticals Major Business
Table 112. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 113. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 114. Shanghai Allist Pharmaceuticals Recent Developments/Updates
Table 115. Innocare Basic Information, Manufacturing Base and Competitors
Table 116. Innocare Major Business
Table 117. Innocare New Molecular Entities (NME) Drugs Product and Services
Table 118. Innocare New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 119. Innocare Recent Developments/Updates
Table 120. Huiyu Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 121. Huiyu Pharmaceuticals Major Business
Table 122. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 123. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 124. Huiyu Pharmaceuticals Recent Developments/Updates
Table 125. Global New Molecular Entities (NME) Drugs Sales Quantity by Manufacturer (2021-2026) & (M Units)
Table 126. Global New Molecular Entities (NME) Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 127. Global New Molecular Entities (NME) Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 128. Market Position of Manufacturers in New Molecular Entities (NME) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 129. Head Office and New Molecular Entities (NME) Drugs Production Site of Key Manufacturer
Table 130. New Molecular Entities (NME) Drugs Market: Company Product Type Footprint
Table 131. New Molecular Entities (NME) Drugs Market: Company Product Application Footprint
Table 132. New Molecular Entities (NME) Drugs New Market Entrants and Barriers to Market Entry
Table 133. New Molecular Entities (NME) Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 134. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 135. Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2026) & (M Units)
Table 136. Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2027-2032) & (M Units)
Table 137. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 138. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 139. Global New Molecular Entities (NME) Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 140. Global New Molecular Entities (NME) Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 141. Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 142. Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 143. Global New Molecular Entities (NME) Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 144. Global New Molecular Entities (NME) Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 145. Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 146. Global New Molecular Entities (NME) Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 147. Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 148. Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 149. Global New Molecular Entities (NME) Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 150. Global New Molecular Entities (NME) Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 151. Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 152. Global New Molecular Entities (NME) Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 153. North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 154. North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 155. North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 156. North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 157. North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 158. North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 159. North America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 160. North America New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 161. Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 162. Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 163. Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 164. Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 165. Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 166. Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 167. Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 168. Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 169. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 170. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 171. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 172. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 173. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2026) & (M Units)
Table 174. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2027-2032) & (M Units)
Table 175. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 176. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 177. South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 178. South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 179. South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 180. South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 181. South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 182. South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 183. South America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 184. South America New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 185. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 186. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 187. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 188. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 189. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 190. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 191. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 192. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 193. New Molecular Entities (NME) Drugs Raw Material
Table 194. Key Manufacturers of New Molecular Entities (NME) Drugs Raw Materials
Table 195. New Molecular Entities (NME) Drugs Typical Distributors
Table 196. New Molecular Entities (NME) Drugs Typical Customers
Table 1. Global New Molecular Entities (NME) Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global New Molecular Entities (NME) Drugs Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global New Molecular Entities (NME) Drugs Consumption Value by Action Mechanism, (USD Million), 2021 & 2025 & 2032
Table 4. Global New Molecular Entities (NME) Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Roche Basic Information, Manufacturing Base and Competitors
Table 6. Roche Major Business
Table 7. Roche New Molecular Entities (NME) Drugs Product and Services
Table 8. Roche New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Roche Recent Developments/Updates
Table 10. Novartis Basic Information, Manufacturing Base and Competitors
Table 11. Novartis Major Business
Table 12. Novartis New Molecular Entities (NME) Drugs Product and Services
Table 13. Novartis New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Novartis Recent Developments/Updates
Table 15. Merck Basic Information, Manufacturing Base and Competitors
Table 16. Merck Major Business
Table 17. Merck New Molecular Entities (NME) Drugs Product and Services
Table 18. Merck New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Merck Recent Developments/Updates
Table 20. Pfizer Basic Information, Manufacturing Base and Competitors
Table 21. Pfizer Major Business
Table 22. Pfizer New Molecular Entities (NME) Drugs Product and Services
Table 23. Pfizer New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Pfizer Recent Developments/Updates
Table 25. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 26. AstraZeneca Major Business
Table 27. AstraZeneca New Molecular Entities (NME) Drugs Product and Services
Table 28. AstraZeneca New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. AstraZeneca Recent Developments/Updates
Table 30. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 31. Johnson & Johnson Major Business
Table 32. Johnson & Johnson New Molecular Entities (NME) Drugs Product and Services
Table 33. Johnson & Johnson New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Johnson & Johnson Recent Developments/Updates
Table 35. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 36. Bristol Myers Squibb Major Business
Table 37. Bristol Myers Squibb New Molecular Entities (NME) Drugs Product and Services
Table 38. Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Bristol Myers Squibb Recent Developments/Updates
Table 40. Bayer Basic Information, Manufacturing Base and Competitors
Table 41. Bayer Major Business
Table 42. Bayer New Molecular Entities (NME) Drugs Product and Services
Table 43. Bayer New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Bayer Recent Developments/Updates
Table 45. GSK Basic Information, Manufacturing Base and Competitors
Table 46. GSK Major Business
Table 47. GSK New Molecular Entities (NME) Drugs Product and Services
Table 48. GSK New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. GSK Recent Developments/Updates
Table 50. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 51. Daiichi Sankyo Major Business
Table 52. Daiichi Sankyo New Molecular Entities (NME) Drugs Product and Services
Table 53. Daiichi Sankyo New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Daiichi Sankyo Recent Developments/Updates
Table 55. Amgen Basic Information, Manufacturing Base and Competitors
Table 56. Amgen Major Business
Table 57. Amgen New Molecular Entities (NME) Drugs Product and Services
Table 58. Amgen New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. Amgen Recent Developments/Updates
Table 60. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 61. Eli Lilly and Company Major Business
Table 62. Eli Lilly and Company New Molecular Entities (NME) Drugs Product and Services
Table 63. Eli Lilly and Company New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Eli Lilly and Company Recent Developments/Updates
Table 65. AbbVie Basic Information, Manufacturing Base and Competitors
Table 66. AbbVie Major Business
Table 67. AbbVie New Molecular Entities (NME) Drugs Product and Services
Table 68. AbbVie New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. AbbVie Recent Developments/Updates
Table 70. Sanofi Basic Information, Manufacturing Base and Competitors
Table 71. Sanofi Major Business
Table 72. Sanofi New Molecular Entities (NME) Drugs Product and Services
Table 73. Sanofi New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Sanofi Recent Developments/Updates
Table 75. Takeda Basic Information, Manufacturing Base and Competitors
Table 76. Takeda Major Business
Table 77. Takeda New Molecular Entities (NME) Drugs Product and Services
Table 78. Takeda New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Takeda Recent Developments/Updates
Table 80. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 81. Boehringer Ingelheim Major Business
Table 82. Boehringer Ingelheim New Molecular Entities (NME) Drugs Product and Services
Table 83. Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Beigene, Ltd. Basic Information, Manufacturing Base and Competitors
Table 86. Beigene, Ltd. Major Business
Table 87. Beigene, Ltd. New Molecular Entities (NME) Drugs Product and Services
Table 88. Beigene, Ltd. New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 89. Beigene, Ltd. Recent Developments/Updates
Table 90. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 91. Jiangsu Hengrui Medicine Major Business
Table 92. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product and Services
Table 93. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 94. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 95. INNOVENT BIOLOGICS(SUZHOU) Basic Information, Manufacturing Base and Competitors
Table 96. INNOVENT BIOLOGICS(SUZHOU) Major Business
Table 97. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product and Services
Table 98. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 99. INNOVENT BIOLOGICS(SUZHOU) Recent Developments/Updates
Table 100. Betta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 101. Betta Pharmaceuticals Major Business
Table 102. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 103. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Betta Pharmaceuticals Recent Developments/Updates
Table 105. Remegen Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 106. Remegen Co.,Ltd. Major Business
Table 107. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product and Services
Table 108. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Remegen Co.,Ltd. Recent Developments/Updates
Table 110. Shanghai Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 111. Shanghai Allist Pharmaceuticals Major Business
Table 112. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 113. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 114. Shanghai Allist Pharmaceuticals Recent Developments/Updates
Table 115. Innocare Basic Information, Manufacturing Base and Competitors
Table 116. Innocare Major Business
Table 117. Innocare New Molecular Entities (NME) Drugs Product and Services
Table 118. Innocare New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 119. Innocare Recent Developments/Updates
Table 120. Huiyu Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 121. Huiyu Pharmaceuticals Major Business
Table 122. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product and Services
Table 123. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 124. Huiyu Pharmaceuticals Recent Developments/Updates
Table 125. Global New Molecular Entities (NME) Drugs Sales Quantity by Manufacturer (2021-2026) & (M Units)
Table 126. Global New Molecular Entities (NME) Drugs Revenue by Manufacturer (2021-2026) & (USD Million)
Table 127. Global New Molecular Entities (NME) Drugs Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 128. Market Position of Manufacturers in New Molecular Entities (NME) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 129. Head Office and New Molecular Entities (NME) Drugs Production Site of Key Manufacturer
Table 130. New Molecular Entities (NME) Drugs Market: Company Product Type Footprint
Table 131. New Molecular Entities (NME) Drugs Market: Company Product Application Footprint
Table 132. New Molecular Entities (NME) Drugs New Market Entrants and Barriers to Market Entry
Table 133. New Molecular Entities (NME) Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 134. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 135. Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2026) & (M Units)
Table 136. Global New Molecular Entities (NME) Drugs Sales Quantity by Region (2027-2032) & (M Units)
Table 137. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 138. Global New Molecular Entities (NME) Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 139. Global New Molecular Entities (NME) Drugs Average Price by Region (2021-2026) & (US$/Unit)
Table 140. Global New Molecular Entities (NME) Drugs Average Price by Region (2027-2032) & (US$/Unit)
Table 141. Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 142. Global New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 143. Global New Molecular Entities (NME) Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 144. Global New Molecular Entities (NME) Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 145. Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2026) & (US$/Unit)
Table 146. Global New Molecular Entities (NME) Drugs Average Price by Type (2027-2032) & (US$/Unit)
Table 147. Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 148. Global New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 149. Global New Molecular Entities (NME) Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 150. Global New Molecular Entities (NME) Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 151. Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2026) & (US$/Unit)
Table 152. Global New Molecular Entities (NME) Drugs Average Price by Application (2027-2032) & (US$/Unit)
Table 153. North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 154. North America New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 155. North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 156. North America New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 157. North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 158. North America New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 159. North America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 160. North America New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 161. Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 162. Europe New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 163. Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 164. Europe New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 165. Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 166. Europe New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 167. Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 168. Europe New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 169. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 170. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 171. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 172. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 173. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2021-2026) & (M Units)
Table 174. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity by Region (2027-2032) & (M Units)
Table 175. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 176. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 177. South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 178. South America New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 179. South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 180. South America New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 181. South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 182. South America New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 183. South America New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 184. South America New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 185. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2021-2026) & (M Units)
Table 186. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Type (2027-2032) & (M Units)
Table 187. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2021-2026) & (M Units)
Table 188. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Application (2027-2032) & (M Units)
Table 189. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2021-2026) & (M Units)
Table 190. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity by Country (2027-2032) & (M Units)
Table 191. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 192. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 193. New Molecular Entities (NME) Drugs Raw Material
Table 194. Key Manufacturers of New Molecular Entities (NME) Drugs Raw Materials
Table 195. New Molecular Entities (NME) Drugs Typical Distributors
Table 196. New Molecular Entities (NME) Drugs Typical Customers
LIST OF FIGURES
Figure 1. New Molecular Entities (NME) Drugs Picture
Figure 2. Global New Molecular Entities (NME) Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type in 2025
Figure 4. Small Molecules Examples
Figure 5. Monoclonal Antibodies Examples
Figure 6. ADCs Examples
Figure 7. Others Examples
Figure 8. Global New Molecular Entities (NME) Drugs Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 9. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route in 2025
Figure 10. Oral Drugs Examples
Figure 11. Injectable Drugs Examples
Figure 12. Others Examples
Figure 13. Global New Molecular Entities (NME) Drugs Revenue by Action Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 14. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism in 2025
Figure 15. Receptor Agonists Examples
Figure 16. Enzyme Inhibitors Examples
Figure 17. Others Examples
Figure 18. Global New Molecular Entities (NME) Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application in 2025
Figure 20. Cancer Diseases Examples
Figure 21. Immune Diseases Examples
Figure 22. Cardiovascular Diseases Examples
Figure 23. Others Examples
Figure 24. Global New Molecular Entities (NME) Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 25. Global New Molecular Entities (NME) Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 26. Global New Molecular Entities (NME) Drugs Sales Quantity (2021-2032) & (M Units)
Figure 27. Global New Molecular Entities (NME) Drugs Price (2021-2032) & (US$/Unit)
Figure 28. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 29. Global New Molecular Entities (NME) Drugs Revenue Market Share by Manufacturer in 2025
Figure 30. Producer Shipments of New Molecular Entities (NME) Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 31. Top 3 New Molecular Entities (NME) Drugs Manufacturer (Revenue) Market Share in 2025
Figure 32. Top 6 New Molecular Entities (NME) Drugs Manufacturer (Revenue) Market Share in 2025
Figure 33. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 34. Global New Molecular Entities (NME) Drugs Consumption Value Market Share by Region (2021-2032)
Figure 35. North America New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Europe New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 37. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 38. South America New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 39. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 40. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 41. Global New Molecular Entities (NME) Drugs Consumption Value Market Share by Type (2021-2032)
Figure 42. Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 43. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 44. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2021-2032)
Figure 45. Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 46. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 47. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 48. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 49. North America New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 50. United States New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Canada New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Mexico New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 54. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 55. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 56. Europe New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 57. Germany New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. France New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. United Kingdom New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. Russia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Italy New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 63. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 64. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 65. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value Market Share by Region (2021-2032)
Figure 66. China New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. Japan New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. South Korea New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. India New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Southeast Asia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 71. Australia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 72. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 73. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 74. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 75. South America New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 76. Brazil New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Argentina New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 79. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 80. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 81. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 82. Turkey New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 83. Egypt New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 84. Saudi Arabia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 85. South Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 86. New Molecular Entities (NME) Drugs Market Drivers
Figure 87. New Molecular Entities (NME) Drugs Market Restraints
Figure 88. New Molecular Entities (NME) Drugs Market Trends
Figure 89. Porters Five Forces Analysis
Figure 90. Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs in 2025
Figure 91. Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
Figure 92. New Molecular Entities (NME) Drugs Industrial Chain
Figure 93. Sales Channel: Direct to End-User vs Distributors
Figure 94. Direct Channel Pros & Cons
Figure 95. Indirect Channel Pros & Cons
Figure 96. Methodology
Figure 97. Research Process and Data Source
Figure 1. New Molecular Entities (NME) Drugs Picture
Figure 2. Global New Molecular Entities (NME) Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type in 2025
Figure 4. Small Molecules Examples
Figure 5. Monoclonal Antibodies Examples
Figure 6. ADCs Examples
Figure 7. Others Examples
Figure 8. Global New Molecular Entities (NME) Drugs Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 9. Global New Molecular Entities (NME) Drugs Revenue Market Share by Administration Route in 2025
Figure 10. Oral Drugs Examples
Figure 11. Injectable Drugs Examples
Figure 12. Others Examples
Figure 13. Global New Molecular Entities (NME) Drugs Revenue by Action Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 14. Global New Molecular Entities (NME) Drugs Revenue Market Share by Action Mechanism in 2025
Figure 15. Receptor Agonists Examples
Figure 16. Enzyme Inhibitors Examples
Figure 17. Others Examples
Figure 18. Global New Molecular Entities (NME) Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application in 2025
Figure 20. Cancer Diseases Examples
Figure 21. Immune Diseases Examples
Figure 22. Cardiovascular Diseases Examples
Figure 23. Others Examples
Figure 24. Global New Molecular Entities (NME) Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 25. Global New Molecular Entities (NME) Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 26. Global New Molecular Entities (NME) Drugs Sales Quantity (2021-2032) & (M Units)
Figure 27. Global New Molecular Entities (NME) Drugs Price (2021-2032) & (US$/Unit)
Figure 28. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Manufacturer in 2025
Figure 29. Global New Molecular Entities (NME) Drugs Revenue Market Share by Manufacturer in 2025
Figure 30. Producer Shipments of New Molecular Entities (NME) Drugs by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 31. Top 3 New Molecular Entities (NME) Drugs Manufacturer (Revenue) Market Share in 2025
Figure 32. Top 6 New Molecular Entities (NME) Drugs Manufacturer (Revenue) Market Share in 2025
Figure 33. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 34. Global New Molecular Entities (NME) Drugs Consumption Value Market Share by Region (2021-2032)
Figure 35. North America New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 36. Europe New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 37. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 38. South America New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 39. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 40. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 41. Global New Molecular Entities (NME) Drugs Consumption Value Market Share by Type (2021-2032)
Figure 42. Global New Molecular Entities (NME) Drugs Average Price by Type (2021-2032) & (US$/Unit)
Figure 43. Global New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 44. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2021-2032)
Figure 45. Global New Molecular Entities (NME) Drugs Average Price by Application (2021-2032) & (US$/Unit)
Figure 46. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 47. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 48. North America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 49. North America New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 50. United States New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Canada New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 52. Mexico New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 54. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 55. Europe New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 56. Europe New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 57. Germany New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. France New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. United Kingdom New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 60. Russia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Italy New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 63. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 64. Asia-Pacific New Molecular Entities (NME) Drugs Sales Quantity Market Share by Region (2021-2032)
Figure 65. Asia-Pacific New Molecular Entities (NME) Drugs Consumption Value Market Share by Region (2021-2032)
Figure 66. China New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. Japan New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. South Korea New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 69. India New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Southeast Asia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 71. Australia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 72. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 73. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 74. South America New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 75. South America New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 76. Brazil New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Argentina New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Type (2021-2032)
Figure 79. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Application (2021-2032)
Figure 80. Middle East & Africa New Molecular Entities (NME) Drugs Sales Quantity Market Share by Country (2021-2032)
Figure 81. Middle East & Africa New Molecular Entities (NME) Drugs Consumption Value Market Share by Country (2021-2032)
Figure 82. Turkey New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 83. Egypt New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 84. Saudi Arabia New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 85. South Africa New Molecular Entities (NME) Drugs Consumption Value (2021-2032) & (USD Million)
Figure 86. New Molecular Entities (NME) Drugs Market Drivers
Figure 87. New Molecular Entities (NME) Drugs Market Restraints
Figure 88. New Molecular Entities (NME) Drugs Market Trends
Figure 89. Porters Five Forces Analysis
Figure 90. Manufacturing Cost Structure Analysis of New Molecular Entities (NME) Drugs in 2025
Figure 91. Manufacturing Process Analysis of New Molecular Entities (NME) Drugs
Figure 92. New Molecular Entities (NME) Drugs Industrial Chain
Figure 93. Sales Channel: Direct to End-User vs Distributors
Figure 94. Direct Channel Pros & Cons
Figure 95. Indirect Channel Pros & Cons
Figure 96. Methodology
Figure 97. Research Process and Data Source
